Drug recalls (page 2)

748 recalls.

• Artificial Tears Sterile Lubricant Eye Drops recall (K.C. Pharmaceuticals, Inc.)
  DrugClass IIReported October 14, 2026 · Lack of Assurance of Sterility
• Benzoyl Peroxide Wash recall (SV Labs Toronto Corporation)
  DrugClass IIReported October 7, 2026 · Microbial contamination of topical product.
• Benzoyl Peroxide Wash recall (SV Labs Toronto Corporation)
  DrugClass IIReported October 7, 2026 · Microbial contamination of topical product.
• Paroxetine Extended-Release Tablets recall (Apotex Corp.)
  DrugClass IIReported October 7, 2026 · Failed dissolution specifications.
• Buprenorphine Hydrochloride recall (Par Health USA, LLC)
  DrugClass IIReported October 7, 2026 · Crystallization
• Zoladex recall (TerSera Therapeutics LLC)
  DrugClass IIReported October 7, 2026 · Temperature Abuse: Product sat in a non-temperature-controlled FedEx trailer at ambient outdoor conditions for 25.5 hours.
• FOCUS PI Hypromellose 0.7% Formula recall (Aurolab Trust)
  DrugClass IIReported October 7, 2026 · Lack of Assurance of Sterility
• Estradiol Gel recall (Amneal Pharmaceuticals, LLC)
  DrugClass IIReported October 7, 2026 · Defective Container; packets were found to be either empty or partially full.
• Ranolazine Extended-Release Tablets recall (Ajanta Pharma USA Inc)
  DrugClass IIReported October 7, 2026 · Failed Dissolution Specifications: below specification
• Clear Eyes Redness Relief recall (Insight Pharmaceuticals LLC, a Prestige Consumer Healthcare company)
  DrugClass IIReported September 30, 2026 · Lack of Assurance of Sterility
• Clear Eyes Redness Relief recall (Insight Pharmaceuticals LLC, a Prestige Consumer Healthcare company)
  DrugClass IIReported September 30, 2026 · Lack of Assurance of Sterility
• Exenatide Injection recall (Amneal Pharmaceuticals of New York, LLC)
  DrugClass IIReported September 30, 2026 · Defective Delivery System: Possibility of no medication in the prefilled pen.
• Olanzapine Tablets recall (Macleods Pharmaceuticals Limited)
  DrugClass IIIReported September 30, 2026 · Failed Impurities/Degradation Specifications:Organic and unspecified impurities above specification.
• AvKare Carboxymethylcellulose Sodium Ophthalmic Solution 0.5% recall (Sterling Pharmaceutical Services LLC)
  DrugClass IIReported September 30, 2026 · Lack of Assurance of Sterility
• Lubricant Eye Drops-Cameron Pharmaceuticals recall (Sterling Pharmaceutical Services LLC)
  DrugClass IIReported September 30, 2026 · Lack of Assurance of Sterility
• Major LubriFresh P.M. Nighttime Ointment recall (Sterling Pharmaceutical Services LLC)
  DrugClass IIReported September 30, 2026 · Lack of Assurance of Sterility
• TRP The Relief Products* Gentle Eyes Lubricant Eye Drops recall (Sterling Pharmaceutical Services LLC)
  DrugClass IIReported September 30, 2026 · Lack of Assurance of Sterility
• Reliable-1 Laboratories Lubricating Tears recall (Sterling Pharmaceutical Services LLC)
  DrugClass IIReported September 30, 2026 · Lack of Assurance of Sterility
• Walgreens Lubricant Eye Drops recall (Sterling Pharmaceutical Services LLC)
  DrugClass IIReported September 30, 2026 · Lack of Assurance of Sterility
• Walgreens Lubricant Eye Drops recall (Sterling Pharmaceutical Services LLC)
  DrugClass IIReported September 30, 2026 · Lack of Assurance of Sterility
• Reliable -1 Laboratories recall (Sterling Pharmaceutical Services LLC)
  DrugClass IIReported September 30, 2026 · Lack of Assurance of Sterility
• AvKare Carboxymethylcellulose Sodium Ophthalmic Solution 0.5% recall (Sterling Pharmaceutical Services LLC)
  DrugClass IIReported September 30, 2026 · Lack of Assurance of Sterility
• MENOW SUNSCREEN PRESSED POWDER SPF35 PA+++ recall (SHANTOU Qiwei industrial Co., Ltd)
  DrugClass IIReported September 30, 2026 · cGMP Deviations
• Thyroid Tablets recall (VITRUVIAS THERAPEUTICS INC)
  DrugClass IReported September 23, 2026 · Superpotent Drug
• Dopamine HCl Inj. recall (Pfizer)
  DrugClass IIReported September 23, 2026 · Lack of Assurance of Sterility
• Chlorthalidone Tablets recall (Inventia Healthcare Limited)
  DrugClass IIReported September 23, 2026 · Failed Dissolution Specifications
• Lidocaine Ointment USP recall (SUN PHARMA /TARO)
  DrugClass IIReported September 23, 2026 · Failed Content Uniformity Specifications. Out of Specification for Assay during analysis at the 24- month long term stability station, at (25¿C,60%RH).
• Fluphenazine HCl Elixir recall (Safecor Health, LLC)
  DrugClass IIReported September 23, 2026 · Failed Stability Specifications
• Fluphenazine HCl Elixir recall (Safecor Health, LLC)
  DrugClass IIReported September 23, 2026 · Failed Stability Specifications
• Fluphenazine HCl Elixir recall (Safecor Health, LLC)
  DrugClass IIReported September 23, 2026 · Failed Stability Specifications
• Fluphenazine HCl Elixir recall (Safecor Health, LLC)
  DrugClass IIReported September 23, 2026 · Failed Stability Specifications
• Fluphenazine HCl Elixir recall (Safecor Health, LLC)
  DrugClass IIReported September 23, 2026 · Failed Stability Specifications
• Fluphenazine HCl Elixir recall (Safecor Health, LLC)
  DrugClass IIReported September 23, 2026 · Failed Stability Specifications
• 0.9% Sodium Chloride Injection recall (B BRAUN MEDICAL INC)
  DrugClass IReported September 16, 2026 · Presence of Particulate Matter: particulate matter identified as iron oxide, inorganic material, cellulose cotton fiber or polystyrene
• Epinephrine Injection recall (American Regent, Inc.)
  DrugClass IReported September 16, 2026 · Presence of Particulate Matter and Lack of Assurance of Sterility. Particulate matter identified as nylon, cellulosic, acrylic, polyethylene and glass and...
• fentaNYL Citrate recall (OurPharma LLC)
  DrugClass IIReported September 16, 2026 · Labeling: Not Elsewhere Classified: Complaint received on 08/31/2026 regarding the discrepancy of the IV bag expiry (07/31/2026 and 11/30/2026) and the product...
• Dextrose Injection recall (Baxter Healthcare Corporation)
  DrugClass IReported September 16, 2026 · Presence of Particulate Matter: particulate matter identified as stainless steel particles in the solution.
• Fluphenazine Hydrochloride Tablets recall (Ajanta Pharma USA Inc)
  DrugClass IIIReported September 16, 2026 · Failed impurities/degradation specifications: (OOS) for Organic Impurities by HPLC (Impurity-A) during testing at the 18 months long term stability. Result...
• Povidone Iodine 1.25% / Proparacaine HCl 0.5% Ophthalmic Solution recall (ImprimisRx NJ LLC)
  DrugClass IIIReported September 16, 2026 · Subpotent Drug
• Glutathione 200 mg/mL recall (OPTIMAL BALANCE PHARMACY)
  DrugClass IReported September 9, 2026 · Microbial Contamination of Sterile Products - out of specifications results were obtained for bacterial endotoxin.
• 0.9% Sodium Chloride Injection USP 500 mL recall (Baxter Healthcare Corporation)
  DrugClass IReported September 9, 2026 · Presence of particulate matter: Particulates identified as fiberglass
• Prasugrel HCI recall (Golden State Medical Supply Inc.)
  DrugClass IIReported September 9, 2026 · Failed Dissolution Specifications. Notification from the manufacturer that lot is being recalled due to failed dissolution
• Buprenorphine Sublingual Tablets recall (American Health Packaging)
  DrugClass IIIReported September 9, 2026 · Labeling: Label Mix-up
• Prasugrel Tablets recall (Mylan Pharmaceuticals Inc)
  DrugClass IIReported September 9, 2026 · Failed Dissolution Specifications; product failed to meet 18-month stability testing acceptance criteria
• Revcovi recall (Chiesi USA, Inc.)
  DrugClass IIIReported September 9, 2026 · Failed Stability Specifications: Out of specification stability result for the protein concentration profile.
• 2% Chlorhexidine Gluconate* Cloth recall (Sage Products, LLC)
  DrugClass IIReported September 9, 2026 · Cross Contamination with Other Products
• traZODone Hydrochloride Tablets recall (Teva Pharmaceuticals USA, Inc)
  DrugClass IIReported September 9, 2026 · Presence of Foreign Tablets/Capsules
• Trokendi XR recall (Supernus Pharmaceuticals, Inc.)
  DrugClass IIIReported September 9, 2026 · Failed dissolution specifications.
• Carton label: Mycophenolate Mofetil for injection recall (Mylan Pharmaceuticals Inc)
  DrugClass IIReported September 9, 2026 · Failed Dissolution Specifications
• Broadway Joe's Pain Cream recall (Lexia LLC)
  DrugClass IIReported September 9, 2026 · CGMP Deviations: Potential contamination of raw material
• Broadway Joe's Pain Cream recall (Lexia LLC)
  DrugClass IIReported September 9, 2026 · CGMP Deviations: Potential contamination of raw material
• THE ONE SPF 50 INVISIBLE SUNSCREEN GEL recall (Allies Group Inc.)
  DrugClass IIReported September 9, 2026 · Subpotent Product: Firm Testing indicated the affected product may not reliably provide the SPF 50 protection stated on the label.
• THE ONE SPF 50 INVISIBLE SUNSCREEN GEL recall (Allies Group Inc.)
  DrugClass IIReported September 9, 2026 · Subpotent Product: Firm Testing indicated the affected product may not reliably provide the SPF 50 protection stated on the label.
• THE ONE SPF 50 INVISIBLE SUNSCREEN GEL recall (Allies Group Inc.)
  DrugClass IIReported September 9, 2026 · Subpotent Product: Firm Testing indicated the affected product may not reliably provide the SPF 50 protection stated on the label.
• THE ONE SPF 50 INVISIBLE SUNSCREEN GEL recall (Allies Group Inc.)
  DrugClass IIReported September 9, 2026 · Subpotent Product: Firm Testing indicated the affected product may not reliably provide the SPF 50 protection stated on the label.
• Doxylamine Succinate and Pyridoxine HCl Delayed-Release tablets 10 mg/10 mg recall (Bionpharma Inc.)
  DrugClass IIIReported September 9, 2026 · Presence of Foreign Tablets/Capsules
• Daptomycin recall (Baxter Healthcare Corporation)
  DrugClass IIReported September 9, 2026 · CGMP Deviations
• Vancomycin Injection recall (Baxter Healthcare Corporation)
  DrugClass IIReported September 9, 2026 · CGMP Deviations
• Vasopressin recall (Baxter Healthcare Corporation)
  DrugClass IIReported September 9, 2026 · CGMP Deviations
• Clindamycin Injection USP in 5% Dextrose recall (Baxter Healthcare Corporation)
  DrugClass IIReported September 9, 2026 · CGMP Deviations
• Clindamycin Injection USP in 5% Dextrose recall (Baxter Healthcare Corporation)
  DrugClass IIReported September 9, 2026 · CGMP Deviations
• Clindamycin Phosphate in 0.9% Sodium Chloride Injection recall (Baxter Healthcare Corporation)
  DrugClass IIReported September 9, 2026 · CGMP Deviations
• Clindamycin Injection USP in 5% Dextrose recall (Baxter Healthcare Corporation)
  DrugClass IIReported September 9, 2026 · CGMP Deviations
• Nexterone recall (Baxter Healthcare Corporation)
  DrugClass IIReported September 9, 2026 · CGMP Deviations
• CARDENE IV recall (Baxter Healthcare Corporation)
  DrugClass IIReported September 9, 2026 · CGMP Deviations
• Pantoprazole Sodium in 0.9% Sodium Chloride Injection recall (Baxter Healthcare Corporation)
  DrugClass IIReported September 9, 2026 · CGMP Deviations
• Vasopressin recall (Baxter Healthcare Corporation)
  DrugClass IIReported September 9, 2026 · CGMP Deviations
• Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection recall (Baxter Healthcare Corporation)
  DrugClass IIReported September 9, 2026 · CGMP Deviations
• Famotidine Injection in Sodium Chloride Injection recall (Baxter Healthcare Corporation)
  DrugClass IIReported September 9, 2026 · CGMP Deviations
• Clindamycin Injection USP in 5% Dextrose recall (Baxter Healthcare Corporation)
  DrugClass IIReported September 9, 2026 · CGMP Deviations
• Daptomycin recall (Baxter Healthcare Corporation)
  DrugClass IIReported September 9, 2026 · CGMP Deviations
• MYXREDLIN recall (Baxter Healthcare Corporation)
  DrugClass IIReported September 9, 2026 · CGMP Deviations
• Vancomycin Injection recall (Baxter Healthcare Corporation)
  DrugClass IIReported September 9, 2026 · CGMP Deviations
• Lactated Ringer's Injection USP recall (B BRAUN MEDICAL INC)
  DrugClass IReported September 2, 2026 · Presence of Particulate matter.
• Ramipril Capsules USP recall (Hikma Pharmaceuticals USA INC.)
  DrugClass IIReported September 2, 2026 · Failed Impurities/Degradation Specifications: OOS result obtained for a process impurity, dicyclohexylurea (DCU).
• Tyenne recall (Fresenius Kabi USA, LLC)
  DrugClass IReported September 2, 2026 · Presence of particulate matter:An internal investigation at the firm found the product to contain glass particles.
• Paxil CR recall (Apotex Corp.)
  DrugClass IIReported September 2, 2026 · Failed Dissolution Specifications; product failed to meet 24-month stability testing acceptance criteria
• Acthar Gel recall (Mallinckrodt Hospital Products Inc.)
  DrugClass IIReported September 2, 2026 · Presence of particulate matter: glass and stopper piece
• Zicam recall (Church & Dwight Co., Inc.)
  DrugClass IIReported September 2, 2026 · CGMP Deviations; FDA inspection of the contract manufacturer noted out of limit results for microbiological testing
• Clobetasol Propionate Cream USP recall (Lupin Pharmaceuticals Inc.)
  DrugClass IIReported September 2, 2026 · Failed content uniformity specifications.
• Levothyroxine Sodium Tablets recall (ACCORD HEALTHCARE, INC.)
  DrugClass IIReported September 2, 2026 · Subpotent Drug
• Levothyroxine Sodium Tablets recall (ACCORD HEALTHCARE, INC.)
  DrugClass IIReported September 2, 2026 · Subpotent Drug
• Levothyroxine Sodium Tablets recall (ACCORD HEALTHCARE, INC.)
  DrugClass IIReported September 2, 2026 · Subpotent Drug
• Levothyroxine Sodium Tablets recall (ACCORD HEALTHCARE, INC.)
  DrugClass IIReported September 2, 2026 · Subpotent Drug
• Levothyroxine Sodium Tablets recall (ACCORD HEALTHCARE, INC.)
  DrugClass IIReported September 2, 2026 · Subpotent Drug
• Levothyroxine Sodium Tablets recall (ACCORD HEALTHCARE, INC.)
  DrugClass IIReported September 2, 2026 · Subpotent Drug
• Levothyroxine Sodium Tablets recall (ACCORD HEALTHCARE, INC.)
  DrugClass IIReported September 2, 2026 · Subpotent Drug
• Levothyroxine Sodium Tablets recall (ACCORD HEALTHCARE, INC.)
  DrugClass IIReported September 2, 2026 · Subpotent Drug
• Levothyroxine Sodium Tablets recall (ACCORD HEALTHCARE, INC.)
  DrugClass IIReported September 2, 2026 · Subpotent Drug
• Levothyroxine Sodium Tablets recall (ACCORD HEALTHCARE, INC.)
  DrugClass IIReported September 2, 2026 · Subpotent Drug
• Levothyroxine Sodium Tablets recall (ACCORD HEALTHCARE, INC.)
  DrugClass IIReported September 2, 2026 · Subpotent Drug
• Levothyroxine Sodium Tablets recall (ACCORD HEALTHCARE, INC.)
  DrugClass IIReported September 2, 2026 · Subpotent Drug
• niCARdipine Hydrochloride Injection recall (American Regent, Inc.)
  DrugClass IIReported August 26, 2026 · Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde
• Tralement recall (American Regent, Inc.)
  DrugClass IIReported August 26, 2026 · Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde
• Papaverine HCl Injection recall (American Regent, Inc.)
  DrugClass IReported August 26, 2026 · Presence of Particulate Matter: Product contaminated with particulate matter identified as glass and/or paraformaldehyde
• Multrys recall (American Regent, Inc.)
  DrugClass IIReported August 26, 2026 · Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde
• Selenious Acid Injection recall (American Regent, Inc.)
  DrugClass IIReported August 26, 2026 · Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde
• ACETYLCYSTEINE SOLUTION recall (American Regent, Inc.)
  DrugClass IIReported August 26, 2026 · Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde
• ACETYLCYSTEINE SOLUTION recall (American Regent, Inc.)
  DrugClass IIReported August 26, 2026 · Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde
• Atropine Sulfate injection recall (American Regent, Inc.)
  DrugClass IIReported August 26, 2026 · Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde

← NewerOlder →